ArticleHaematologica2019
Relevance of platelet desialylation and thrombocytopenia in type 2B von Willebrand disease: preclinical and clinical evidence.
Article in Haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Comparative Analysis of Pure VWF and VWF/FVIII Complex in Orthopedic Surgery for Type 2B von Willebrand Disease.The American journal of case reports · 2025Article
- The intersection of epigenetics and immune thrombocytopenia: new insights into disease mechanisms and treatments.Molecular biology reports · 2025Review
- Sialic acid and platelet count regulation: Implications in immune thrombocytopenia.Research and practice in thrombosis and haemostasis · 2022Article
- Review
- Dissecting pathways to thrombocytopenia in a mouse model of visceral leishmaniasis.Blood advances · 2021Article
- Platelet desialylation and TFH cells-the novel pathway of immune thrombocytopenia.Experimental hematology & oncology · 2021Review
- The Provocative Roles of Platelets in Liver Disease and Cancer.Frontiers in oncology · 2021Review
- Inherited thrombocytopenias: history, advances and perspectives.Haematologica · 2020Review
- Measuring beta-galactose exposure on platelets: Standardization and healthy reference values.Research and practice in thrombosis and haemostasis · 2020Article
- Hyperactive GPIb-von Willebrand factor interaction as cause of thrombocytopenia: altered platelet formationHaematologica · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with type 2B von Willebrand disease (vWD) (caused by gain-of-function mutations in the gene coding for von Willebrand factor) display bleeding to a variable extent and, in some cases, thrombocytopenia. There are several underlying causes of thrombocytopenia in type 2B vWD. It was recently suggested that desialylation-mediated platelet clearance leads to thrombocytopenia in this disease. However, this hypothesis has not been tested
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.